The initial application of MOTS-c was mainly to alleviate hyperglycemia and insulin resistance [76,77], regulate PGC-1 expression through the AMPK signaling pathway, reduce insulin resistance, and enhance glucose metabolism [78]. This evidence concerns the gene PPARGC1A and Hyperglycemia.